advertisement
Abstract #109829 Published in IGR 24-1
2% Ganciclovir Controlled Posner-Schlossman Syndrome Relapse and Reduced the Chance of Corticosteroid Dependence: A Large Cohort in East China
Sheng Q; Sun Y; Zhai R; Fan X; Ying Y; Kong XOcular Immunology and Inflammation 2023; 0: 1-8
PURPOSE: To present the process from acute Posner-Schlossman syndrome (PSS) relapse to remission under 2% ganciclovir (GCV), corticosteroids and anti-glaucoma agents on 323 patients. METHODS: A retrospective study enrolling 323 PSS patients. Demographics and ophthalmic examination results were generated. Patients were treated with GCV, corticosteroids and anti-glaucoma agents andfollowed up every 2-6 weeks. RESULTS: Patients were divided into the GCV monotherapy ( = 65, 20.12%), GCV and corticosteroids (G+C, = 106) and GCV, corticosteroid and IOP-lowering drugs (G+C+L, = 152) group. The G+C+L group had the highest intraocular pressure (IOP, 26.33 ± 10.26 mmHg, < 0.001) and largest cup-to-disc ratio (0.58 ± 0.19, < 0.05). After treatment, IOP of three groups dropped to similar level. Ninety-nine (30.65%) patients were corticosteroid-dependent whose daily corticosteroid consumption decreased after using GCV (from 2.23 ± 1.02 to 0.97 ± 0.98 drops/day). CONCLUSION: 2% GCV solutions worked effectively on PSS relapse with corticosteroids and anti-glaucoma agents. In patients suspected of CMV infection, proper GCV could reduce the chance of corticosteroid dependence.
Full article
